Menu Back toWho Should Pay for Expanded Access?

DIA 2021 Global Annual Meeting

Who Should Pay for Expanded Access?

Session Chair(s)

Alison Bateman-House, PhD, MA, MPH

Alison Bateman-House, PhD, MA, MPH

  • Assistant Professor, Division of Medical Ethics, Dept of Population Health
  • NYU Grossman School of Medicine, United States
Non-trial preapproval access involves costs: in producing product, in tracking safety and efficacy outcomes, and in developing a fair allocation strategy. Who is currently paying these costs? Who should be paying for these costs, and why?
Learning Objective : Describe legal, regulatory, and ethical issues concerning who should pay for preapproval access-related costs; Identify costs and paying parties within current legal and regulatory frameworks, US and abroad; Evaluate different payment strategies from the perspective of multiple stakeholders.

Speaker(s)

Tom Watson

Panelist

Tom Watson

  • Executive Vice President, Early Access Programs
  • Bionical Emas, United Kingdom
Andrew McFadyen

Panelist

Andrew McFadyen

  • Executive Director
  • The Isaac Foundation, Canada
Christopher Robertson, JD, PhD, LLM

Panelist

Christopher Robertson, JD, PhD, LLM

  • N.Neal Pike Scholar and Professor of Law
  • Boston University, United States